Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
This retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC) who received palbociclib plus an aromatase inhibitor as...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-02-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/2/89 |
| _version_ | 1797481389222789120 |
|---|---|
| author | Jeanna Wallenta Law Debanjali Mitra Henry G. Kaplan Tamuno Alfred Adam M. Brufsky Birol Emir Haley McCracken Xianchen Liu Ronda G. Broome Chenan Zhang Caroline DiCristo Connie Chen |
| author_facet | Jeanna Wallenta Law Debanjali Mitra Henry G. Kaplan Tamuno Alfred Adam M. Brufsky Birol Emir Haley McCracken Xianchen Liu Ronda G. Broome Chenan Zhang Caroline DiCristo Connie Chen |
| author_sort | Jeanna Wallenta Law |
| collection | DOAJ |
| description | This retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC) who received palbociclib plus an aromatase inhibitor as first-line therapy in US community health systems. Using electronic health records from the Syapse Learning Health Network, 242 patients were identified as having received first-line palbociclib plus an aromatase inhibitor between 3 February 2015, and 31 July 2019 (data cutoff 1 February 2020) resulting in a minimum potential 6-month follow-up period. In total, 56.6% of patients had de novo A/MBC at initial breast cancer diagnosis, 50.8% had bone-only disease, and 32.2% had visceral disease. Median follow-up was 22.4 months. Disease progression (26.4%) and intolerance/toxicity (14.9%) were the main reasons for treatment discontinuation. The median (95% CI) real-world progression-free survival was 31.7 (27.9—not estimable (NE)) months and 2-year estimated overall survival (OS) rate was 78.0%. In total, 25.6% of patients died; however, OS data are limited by the small population size and insufficient follow-up time. These real-world effectiveness outcomes complement findings from other real-world studies and randomized controlled trials and support palbociclib plus an aromatase inhibitor as first-line therapy for HR+/HER2− A/MBC. |
| first_indexed | 2024-03-09T22:13:52Z |
| format | Article |
| id | doaj.art-f8c89b12620c474d8fca86acf4db753d |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-09T22:13:52Z |
| publishDate | 2022-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-f8c89b12620c474d8fca86acf4db753d2023-11-23T19:27:16ZengMDPI AGCurrent Oncology1198-00521718-77292022-02-012921047106110.3390/curroncol29020089Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health NetworkJeanna Wallenta Law0Debanjali Mitra1Henry G. Kaplan2Tamuno Alfred3Adam M. Brufsky4Birol Emir5Haley McCracken6Xianchen Liu7Ronda G. Broome8Chenan Zhang9Caroline DiCristo10Connie Chen11Syapse, San Francisco, CA 94107, USAPfizer Inc., New York, NY 10017, USASwedish Cancer Institute, Seattle, WA 98104, USAPfizer Inc., New York, NY 10017, USAComprehensive Breast Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USAPfizer Inc., New York, NY 10017, USASyapse, San Francisco, CA 94107, USAPfizer Inc., New York, NY 10017, USASyapse, San Francisco, CA 94107, USASyapse, San Francisco, CA 94107, USAPfizer Inc., New York, NY 10017, USAPfizer Inc., New York, NY 10017, USAThis retrospective single-arm study assessed real-world treatment patterns and clinical outcomes in patients with hormone receptor—positive/human epidermal growth factor receptor 2—negative (HR+/HER2−) advanced/metastatic breast cancer (A/MBC) who received palbociclib plus an aromatase inhibitor as first-line therapy in US community health systems. Using electronic health records from the Syapse Learning Health Network, 242 patients were identified as having received first-line palbociclib plus an aromatase inhibitor between 3 February 2015, and 31 July 2019 (data cutoff 1 February 2020) resulting in a minimum potential 6-month follow-up period. In total, 56.6% of patients had de novo A/MBC at initial breast cancer diagnosis, 50.8% had bone-only disease, and 32.2% had visceral disease. Median follow-up was 22.4 months. Disease progression (26.4%) and intolerance/toxicity (14.9%) were the main reasons for treatment discontinuation. The median (95% CI) real-world progression-free survival was 31.7 (27.9—not estimable (NE)) months and 2-year estimated overall survival (OS) rate was 78.0%. In total, 25.6% of patients died; however, OS data are limited by the small population size and insufficient follow-up time. These real-world effectiveness outcomes complement findings from other real-world studies and randomized controlled trials and support palbociclib plus an aromatase inhibitor as first-line therapy for HR+/HER2− A/MBC.https://www.mdpi.com/1718-7729/29/2/89HR+/HER2−metastatic breast cancerpalbociclibaromatase inhibitorreal-world data |
| spellingShingle | Jeanna Wallenta Law Debanjali Mitra Henry G. Kaplan Tamuno Alfred Adam M. Brufsky Birol Emir Haley McCracken Xianchen Liu Ronda G. Broome Chenan Zhang Caroline DiCristo Connie Chen Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network Current Oncology HR+/HER2− metastatic breast cancer palbociclib aromatase inhibitor real-world data |
| title | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network |
| title_full | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network |
| title_fullStr | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network |
| title_full_unstemmed | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network |
| title_short | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network |
| title_sort | real world treatment patterns and clinical effectiveness of palbociclib plus an aromatase inhibitor as first line therapy in advanced metastatic breast cancer analysis from the us syapse learning health network |
| topic | HR+/HER2− metastatic breast cancer palbociclib aromatase inhibitor real-world data |
| url | https://www.mdpi.com/1718-7729/29/2/89 |
| work_keys_str_mv | AT jeannawallentalaw realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT debanjalimitra realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT henrygkaplan realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT tamunoalfred realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT adammbrufsky realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT birolemir realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT haleymccracken realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT xianchenliu realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT rondagbroome realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT chenanzhang realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT carolinedicristo realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork AT conniechen realworldtreatmentpatternsandclinicaleffectivenessofpalbociclibplusanaromataseinhibitorasfirstlinetherapyinadvancedmetastaticbreastcanceranalysisfromtheussyapselearninghealthnetwork |